JP7379325B2 - 組織特異的送達用のカチオン性脂質組成物 - Google Patents

組織特異的送達用のカチオン性脂質組成物 Download PDF

Info

Publication number
JP7379325B2
JP7379325B2 JP2020512589A JP2020512589A JP7379325B2 JP 7379325 B2 JP7379325 B2 JP 7379325B2 JP 2020512589 A JP2020512589 A JP 2020512589A JP 2020512589 A JP2020512589 A JP 2020512589A JP 7379325 B2 JP7379325 B2 JP 7379325B2
Authority
JP
Japan
Prior art keywords
molar ratio
lipid
certain embodiments
cationic lipid
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020512589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532546A (ja
JP2020532546A5 (https=
JPWO2019045897A5 (https=
Inventor
シカ ミシュラ
モレラ デュ ジュ グザヴィエ ド
Original Assignee
ライフ テクノロジーズ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフ テクノロジーズ コーポレイション filed Critical ライフ テクノロジーズ コーポレイション
Publication of JP2020532546A publication Critical patent/JP2020532546A/ja
Publication of JP2020532546A5 publication Critical patent/JP2020532546A5/ja
Publication of JPWO2019045897A5 publication Critical patent/JPWO2019045897A5/ja
Priority to JP2023115742A priority Critical patent/JP2023138526A/ja
Application granted granted Critical
Publication of JP7379325B2 publication Critical patent/JP7379325B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020512589A 2017-08-31 2018-07-17 組織特異的送達用のカチオン性脂質組成物 Active JP7379325B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023115742A JP2023138526A (ja) 2017-08-31 2023-07-14 組織特異的送達用のカチオン性脂質組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762552783P 2017-08-31 2017-08-31
US62/552,783 2017-08-31
PCT/US2018/042555 WO2019045897A1 (en) 2017-08-31 2018-07-17 CATIONIC LIPIDIC COMPOSITIONS FOR TISSUE-SPECIFIC ADMINISTRATION

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023115742A Division JP2023138526A (ja) 2017-08-31 2023-07-14 組織特異的送達用のカチオン性脂質組成物

Publications (4)

Publication Number Publication Date
JP2020532546A JP2020532546A (ja) 2020-11-12
JP2020532546A5 JP2020532546A5 (https=) 2022-12-09
JPWO2019045897A5 JPWO2019045897A5 (https=) 2022-12-09
JP7379325B2 true JP7379325B2 (ja) 2023-11-14

Family

ID=63104088

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512589A Active JP7379325B2 (ja) 2017-08-31 2018-07-17 組織特異的送達用のカチオン性脂質組成物
JP2023115742A Pending JP2023138526A (ja) 2017-08-31 2023-07-14 組織特異的送達用のカチオン性脂質組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023115742A Pending JP2023138526A (ja) 2017-08-31 2023-07-14 組織特異的送達用のカチオン性脂質組成物

Country Status (8)

Country Link
US (3) US20190060482A1 (https=)
EP (1) EP3675826B1 (https=)
JP (2) JP7379325B2 (https=)
CN (1) CN111065377A (https=)
AU (1) AU2018324345B2 (https=)
CA (1) CA3073851A1 (https=)
LT (1) LT3675826T (https=)
WO (1) WO2019045897A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11690921B2 (en) * 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2020212522A1 (en) 2019-04-16 2020-10-22 Genfit Compositions and methods for the stabilization of micro-rna
JP7699552B2 (ja) * 2019-07-03 2025-06-27 ファクター バイオサイエンス インコーポレイテッド カチオン性脂質及びその使用
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
EP3865122A1 (en) * 2020-02-11 2021-08-18 Pantherna Therapeutics GmbH Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium
WO2024006937A1 (en) 2022-06-30 2024-01-04 Life Technologies Corporation Lipid compositions for in vivo delivery
EP4642434A2 (en) 2022-12-29 2025-11-05 Life Technologies Corporation Lipid compositions on the basis of ionizable lipids, use for delivery to immune cells
WO2024250133A1 (zh) * 2023-06-05 2024-12-12 安徽医科大学第一附属医院 肺靶向纳米胶束、制备方法及应用
WO2025189064A1 (en) 2024-03-08 2025-09-12 Genzyme Corporation Lipid nanoparticles
WO2026030375A2 (en) 2024-07-30 2026-02-05 Genzyme Corporation Lipid nanoparticles and methods of manufacture and use thereof
CN118576568B (zh) * 2024-08-06 2024-11-26 北京悦康科创医药科技股份有限公司 一种药物组合物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027795A1 (en) 1998-11-12 2000-05-18 Invitrogen Corporation Transfection reagents
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2012068176A1 (en) 2010-11-15 2012-05-24 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
WO2016206626A1 (zh) 2015-06-26 2016-12-29 苏州瑞博生物技术有限公司 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
JP2004512345A (ja) 2000-11-02 2004-04-22 スミスクライン・ビーチャム・コーポレイション 受容体アンタゴニスト−脂質コンジュゲートおよびそれを含有するデリバリービヒクル
AU2002360762A1 (en) 2001-12-19 2003-07-09 Alza Corporation Liposomal tumor necrosis factor compositions
US7745651B2 (en) 2004-06-07 2010-06-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods of use
US20130189364A1 (en) 2004-07-09 2013-07-25 Robert Sabin Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections
GB0418172D0 (en) 2004-08-13 2004-09-15 Ic Vec Ltd Vector
US20110165223A1 (en) * 2008-01-02 2011-07-07 The Johns Hopkins University Antitumor Immunization by Liposomal Delivery of Vaccine to the Spleen
US9029338B2 (en) * 2009-08-14 2015-05-12 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
PL3586861T3 (pl) * 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
GR1008018B (el) 2012-09-06 2013-10-29 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Λιπιδικα συμπλοκα αποτελουμενα απο ανιονικα λυσο-λιπιδια και η εφαρμογη αυτων
CN103296033B (zh) 2013-05-28 2016-05-11 京东方科技集团股份有限公司 一种阵列基板及其制作方法
JP2016528890A (ja) * 2013-07-09 2016-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
SG10201811729PA (en) 2013-12-12 2019-02-27 Life Technologies Corp Membrane-penetrating peptides to enhance transfection and compositions and methods for using same
ES2949540T3 (es) 2015-06-19 2023-09-29 Massachusetts Inst Technology 2,5-piperazinadionas sustituidas con alquenilo y su uso en composiciones para suministrar un agente a un sujeto o una célula
JP2018532404A (ja) 2015-10-14 2018-11-08 ライフ テクノロジーズ コーポレーション リボ核タンパク質トランスフェクション薬剤
US11690921B2 (en) * 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
CN112996519B (zh) * 2018-09-04 2025-02-28 德克萨斯大学系统董事会 用于核酸的器官特异性递送的组合物和方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000027795A1 (en) 1998-11-12 2000-05-18 Invitrogen Corporation Transfection reagents
WO2011076807A2 (en) 2009-12-23 2011-06-30 Novartis Ag Lipids, lipid compositions, and methods of using them
WO2012068176A1 (en) 2010-11-15 2012-05-24 Life Technologies Corporation Amine-containing transfection reagents and methods for making and using same
WO2016011203A1 (en) 2014-07-15 2016-01-21 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
WO2016206626A1 (zh) 2015-06-26 2016-12-29 苏州瑞博生物技术有限公司 一种siRNA、含有该siRNA的药物组合物和缀合物及它们的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARVIE P; ET AL，JOURNAL OF PHARMACEUTICAL SCIENCES，米国，2000年05月，VOL:89, NR:5，PAGE(S):652 - 663，http://dx.doi.org/10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO;2-H
KOZUE ABE; ET AL，COLLOIDS AND SURFACES A: PHYSIOCHEMICAL AND ENGINEERING ASPECTS，NL，2015年06月，VOL:474，PAGE(S):63 - 70，http://dx.doi.org/10.1016/j.colsurfa.2015.03.006

Also Published As

Publication number Publication date
WO2019045897A1 (en) 2019-03-07
JP2020532546A (ja) 2020-11-12
US20220001023A1 (en) 2022-01-06
JP2023138526A (ja) 2023-10-02
EP3675826B1 (en) 2023-05-31
US20190060482A1 (en) 2019-02-28
LT3675826T (lt) 2023-09-11
CN111065377A (zh) 2020-04-24
US20260108623A1 (en) 2026-04-23
AU2018324345B2 (en) 2024-06-27
CA3073851A1 (en) 2019-03-07
AU2018324345A1 (en) 2020-03-05
US12521447B2 (en) 2026-01-13
EP3675826A1 (en) 2020-07-08

Similar Documents

Publication Publication Date Title
JP7379325B2 (ja) 組織特異的送達用のカチオン性脂質組成物
Kulkarni et al. Lipid nanoparticle technology for clinical translation of siRNA therapeutics
JP6746726B2 (ja) 脂質組成物
CN113710799B (zh) 用于在LNP中使用的编码CAS9的优化mRNA
JP6382380B2 (ja) 免疫細胞へオリゴヌクレオチドを送達する方法
JP2022518504A (ja) 閉端ｄｎａ（ｃｅｄｎａ）ならびに遺伝子療法または核酸療法に関連する免疫応答を低減させる方法における使用
US20240197636A1 (en) Tissue-specific nucleic acid delivery by mixed cationic lipid particles
US20240115730A1 (en) Tissue-specific nucleic acid delivery by 1,2-dioleoyl-3-trimethylammonium-propane (dotap) lipid nanoparticles
Li et al. Design strategies for novel lipid nanoparticle for mRNA vaccine and therapeutics: Current understandings and future perspectives
WO2021231827A2 (en) Sirna sequences targeting coronavirus-2
JP2025501905A (ja) イオン化脂質、脂質ナノ粒子、及びこれらの使用
WO2014030601A1 (ja) アニオン性を有する新規ナノバブルポリ－リポ・プレックスの製造方法
KR20130049668A (ko) 저밀도 지단백질 유사 양이온성 나노입자로 된 혈액 뇌 장벽（ｂｂｂ） 수송 벡터

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220704

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220930

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230714

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230825

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231002

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231101

R150 Certificate of patent or registration of utility model

Ref document number: 7379325

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150